Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

New England Journal of Medicine

Volumn 327, Issue 21, 1992, Pages 1478-1484

  Canellos, George P ^a   Anderson, James R ^b   Propert, Kathleen J ^c   Nissen, Nis ^d   Cooper, M Robert ^e   Henderson, Edward S ^f   Green, Mark R ^g   Gottlieb, Arlan ^h   Peterson, Bruce A ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Rigshospitalet   (Denmark)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PRIORITY JOURNAL; RELAPSE; THROMBOCYTE COUNT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMPARATIVE STUDY; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MECHLORETHAMINE; MIDDLE AGE; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; SUPPORT, U.S. GOV'T, P.H.S.; VINCRISTINE;

EID: 0026439199     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199211193272102     Document Type: Article

References (29)

1. DeVita VT Jr, Serpick AA, Carbone pp. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881–95.
2. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–306.
3. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173–86.
4. Wagstaff J, Gregory WM, Swindell R, Crowther D, Lister TA. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 1988; 58: 487–92.
5. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–53.
6. van Rijswijk PEN, Haanen C, Dekker AW, de Meijer AJ, Verbeek J. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–82.
7. Pillai GN, Hagemeister FB, Velasquez WS, et al. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer 1985; 55: 691–7.
8. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76–81.
9. Waxman JHX, Terry YA, Wrigley PFM, et al. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. BMJ 1982; 285: 1612–3.
10. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71: 552–6.
11. Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990; 62: 279–85.
12. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–9.
13. Sutcliffe SB, Wrigley PFM, Stansfeld AG, Malpas JS. Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP). Cancer Chemother Pharmacol 1979; 2: 209–13.
14. Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 1984; 101: 440–6.
15. Papa G, Mandelli F, Anselmo AP, et al. Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Eur J Cancer Clin Oncol 1982; 18: 803–6.
16. Piga A, Ambroserti A, Todeschini G, Cetto G, Perona G, Cellerino R. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)resistant advanced Hodgkin's disease. Cancer Treat Rep 1984; 68: 947–51.
17. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601–5.
18. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830–7.
19. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med 1986; 104: 739–46.
20. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–6.
21. Erratum, J Clin Oncol 1990; 8: 1602.
22. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27–37.
23. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley, 1973.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
25. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39.
26. Bakermeier RJ, Anderson JR, Costello W, et al. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group study. Ann Intern Med 1984; 101: 447–56.
27. Burgers JMV, Somers R, Henry-Amar M, et al. Management of relapse and survival in advanced stage Hodgkin's disease: the EORTC experience. Ann Oncol 1991; 2: Suppl 2: 63–6.
28. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1174–82.
29. Glick J, Tsiatis A, Schilsky R, et al. A randomized phase III trial of MOPP/ABV hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: preliminary results of the intergroup trial. Proc Am Soc Clin Oncol 1991; 10: 271. abstract.